Clinical Trials on Submental Fullness

Total 2625 results

Allergan

Terminated

Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

Submental Fullness

Korea, Republic of
Kythera Biopharmaceuticals

Completed

Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)

Submental Fullness

United States, Canada
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Raziel Therapeutics Ltd.

Completed

An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.

Submental Fat

United States
Raziel Therapeutics Ltd.

Completed

An Open-label Study That Will Test a Second Treatment Session of RZL-012.

Submental Fat

United States
Medy-Tox

Completed

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Submental Fat

Korea, Republic of
Medy-Tox

Completed

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Submental Fat

Korea, Republic of
Neothetics, Inc

Completed

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Submental Fat

United States
10xBio, LLC

Completed

A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")

Submental Fat

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (SMF)

Submental Fat

Korea, Republic of
Raziel Therapeutics Ltd.

Completed

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Submental Fat

United States
Raziel Therapeutics Ltd.

Completed

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Submental Fat

United States
Raziel Therapeutics Ltd.

Completed

A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.

Submental Fat

United States
10xBio, LLC

Active, not recruiting

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

Submental Fat

United States
Syneron Medical

Unknown

Treatment With the Profound System for Submental Laxity

Submental Laxity

United States
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Kythera Biopharmaceuticals

Completed

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada
AMIpharm Co., Ltd.

Completed

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

Healthy Subjects | Submental Fat

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Completed

Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat (SMF)

Treatment for Submental Fat

Korea, Republic of
Rejuven Dermaceutical Co., Ltd.

Completed

RJV001 Study in Adults Receiving Abdominoplasty

Submental Fat (SMF) | Double Chin

United States
Topokine Therapeutics, Inc.

Suspended

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

Excess Submental Fat ("Double Chin")
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Kythera Biopharmaceuticals

Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Cairo University

Unknown

Effect of the Submental Artery Island Flap Versus Maxillary Obturator Prosthesis

Patient With Partial Maxillectomy | Submental Island Flap | Maxillary Obturator

Egypt
Genzyme, a Sanofi Company

Completed

A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) (FSGS)

Primary Focal Segmental Glomerulosclerosis

United States, Brazil, Germany, Italy, Spain
Complexa, Inc.
Medpace, Inc.; MicroConstants; Kidney Research Network, formerly NephCure Accelerating... and other collaborators

Completed

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

Primary Focal Segmental Glomerulosclerosis

United States
National Institute of Diabetes and Digestive and...
Genentech, Inc.; Indiana University

Completed

Rituximab Treatment of Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis (FSGS)

United States
The University of Texas Medical Branch, Galveston
United States Department of Defense

Completed

Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects

Segmental Long Bone Defects

United States
Mayo Clinic
University Health Network, Toronto; National Institute of Diabetes and Digestive... and other collaborators

Completed

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Primary Focal Segmental Glomerulosclerosis

Canada, United States
Mallinckrodt ARD LLC

Completed

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria (PODOCYTE)

Idiopathic Focal Segmental Glomerulosclerosis

United States, Argentina, Turkey, Peru, Australia, Chile, Mexico
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaborators

Completed

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (FONTII)

Focal Segmental Glomerulosclerosis

United States, Canada
Northwell Health

Terminated

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Focal Segmental Glomerulosclerosis
FibroGen

Terminated

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis

United States
Genzyme, a Sanofi Company

Completed

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Focal Segmental Glomerulosclerosis

United States, Germany, United Kingdom, Italy
Health Science Center of Xi'an Jiaotong University

Unknown

Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis

China
McMaster University

Withdrawn

Iball & Pelvic Floor Muscle Training (iball)

Segmental Dysfunction of the Pelvic Region
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Focal Segmental Glomerulosclerosis (FSGS)

United States
University of California, San Diego

Recruiting

A Case Series: TRUMATCH Graft Cage for Segmental Long Bone Defects

Segmental Long Bone Defect Requiring Surgical Treatment

United States
Nanjing University School of Medicine

Terminated

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis (FSGS)

FSGS

China
Astellas Pharma Global Development, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Kidney Transplantation | Primary Focal Segmental Glomerulosclerosis (FSGS)

United States, Canada

Clinical Trials on Submental Fullness

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations